Humana Inc.
HUMHealthcareNASDAQHealthcare Plans
Scan Results
Daily timeframeHumana Inc. provides medical and specialty insurance products in the United States. The $48.22B market capitalization puts HUM squarely in large-cap range for its industry. It operates in two segments, Insurance and CenterWell.
Market Cap
$48.22B
Beta
0.74
P/E (TTM)
38.02
P/E (Fwd)
24.24
EPS (TTM)
$10.56
EPS (Fwd)
$16.57
ROE
6.9%
ROA
3.9%
Cash
$23.87B
Total Debt
$14.74B
Free CF
$1.94B
52W Change
47.1%
Annual Financials
Cash vs Debt
Where HUM stands vs its 150-day and 200-day moving averages
As of the August 27, 2026 close, HUM finished 39.78% above its 150-day moving average ($279.76) and 43.15% above its 200-day moving average ($273.19). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is HUM overbought or oversold?
At the August 27, 2026 close, HUM's RSI(14) was 64.3, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $23.87B in cash and $14.74B in debt, HUM maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Annual free cash flow of $1.94B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 6.9% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 3.9% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $83.06B (2021) to $129.66B (2025), reflecting a 56% increase over the period.
Investors considering Humana Inc. should weigh the typical risks associated with HUM's sector, size, and financial profile against their own risk tolerance and investment objectives. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Humana Inc.'s trajectory.